

## Direct Thrombin Inhibitors for the Treatment of Heparin-Induced Thrombocytopenia

by Jennifer Namba, Pharm.D.

### References

1. Call JT, Deliargyris EN, Sane DC. Direct thrombin inhibitors in the treatment of immune-mediated heparin-induced thrombocytopenia. *Semin Thromb Hemost* 2004;30(3):297-304.
2. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* 2004;126(3 Suppl):311S-37S.
3. Pravinkumar E, Webster NR. HIT/HITT and alternative anticoagulation: current concepts. *Br J Anaesth* 2003;90(5):676-85.
4. Warkentin TE. Bivalent direct thrombin inhibitors: hirudin and bivalirudin. *Best Pract Res Clin Haematol* 2004;17(1):105-25.
5. Nikolsky E, Dangas GD. Percutaneous interventions in patients with immune-mediated heparin-induced thrombocytopenia. *Semin Thromb Hemost* 2004;30(3):305-14.
6. Greinacher A. The use of direct thrombin inhibitors in cardiovascular surgery in patients with heparin-induced thrombocytopenia. *Semin Thromb Hemost* 2004;30(3):315-27.
7. Kelton JG. The pathophysiology of heparin-induced thrombocytopenia: biological basis for treatment. *Chest* 2005;127(2 Suppl):9S-20S.
8. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. *Am J Med* 1996;101(5):502-7.
9. Warkentin TE. An overview of the heparin-induced thrombocytopenia syndrome. *Semin Thromb Hemost* 2004;30(3):273-83.
10. Hassell K. The management of patients with heparin-induced thrombocytopenia who require anticoagulant therapy. *Chest* 2005;127(2 Suppl):1S-8S.
11. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. *N Engl J Med* 2001;344(17):1286-92.
12. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. *Ann Thorac Surg* 2003;76(6):2121-31.
13. Sciulli TM, Mauro VF. Pharmacology and clinical use of bivalirudin. *Ann Pharmacother* 2002;36(6):1028-41.
14. Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. *Circulation* 1999;99(1):73-80.
15. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. *Circulation* 1999;100(6):587-93.

(Continued on page 2)

---

A University of Washington Drug Information Center publication  
Distributed monthly by authority of the Pharmacy and Therapeutics Committee  
Editor: Nelda A. Murri, Pharm.D. (206) 598-6612 – Asst. Editor: Elizabeth Rudy, D.V.M., R.Ph.  
Department of Pharmacy Services / School of Pharmacy

---

Copyright © 2005 by the University of Washington  
Also published on the World Wide Web at <http://uw.pnrx.org/therapyTopics.asp>  
No material may be reproduced in whole or in part without written permission from the editor.

**References**  
(continued)

16. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. *Blood* 2000;96(3):846-51.
17. Lubenow N, Eichler P, Lietz T, Farner B, Greinacher A. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. *Blood* 2004;104(10):3072-7.
18. Greinacher A, Lubenow N. Recombinant hirudin in clinical practice: focus on lepirudin. *Circulation* 2001;103(10):1479-84.
19. Nowak G, Bucha E, Goock T, Thieler H, Markwardt F. Pharmacology of r-hirudin in renal impairment. *Thromb Res* 1992;66(6):707-15.
20. Wittkowsky A. UWMC Department of Pharmacy drug information: Lepirudin. February 2003.
21. Lepirudin. Package Insert. Berlex Laboratories:October 2004.
22. Eichler P, Friesen HJ, Lubenow N, Jaeger B, Greinacher A. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. *Blood* 2000;96(7):2373-8.
23. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. *Circulation* 2001;103(14):1838-43.
24. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. *Arch Intern Med* 2003;163(15):1849-56.
25. Wittkowsky A. UWMC Department of Pharmacy drug information: Argatroban. February 2003.
26. Messmore H, Jeske W, Wehrmacher W, Walenga J. Benefit-risk assessment of treatments for heparin-induced thrombocytopenia. *Drug Saf* 2003;26(9):625-41.
27. Francis JL DA, Gwyn G, et al. Successful use of bivalirudin in the treatment of patients suspected, or at risk of, heparin-induced thrombocytopenia. In: *Blood*, 103: Abstract 4077; 2004.
28. Bivalirudin. Package Insert. The Medicines Company:October 2005.
29. Wittkowsky A. UWMC Department of Pharmacy personal communication: Bivalirudin. January 2005.
30. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* 2004;126(3 Suppl):401S-28S.